

In this issue . . .

Modern diets and gut microbiome composition

Rich in fat, sugar, and animal protein, the quintessential modern Western diet is often deficient in plant-derived fibers and thought to disrupt the delicate balance of human gut microbes. To explore the effects of diet on gut microbiomes, Jonathan Clayton et al. (pp. 10376–10381) sequenced DNA extracted from fecal samples from two primate species—red-shanked douc and mantled howling monkey—that were raised in zoos, sanctuaries, and nature, representing captive, semicaptive, and wild settings, respectively. Despite being raised on vastly divergent diets in zoos as far-flung as Southeast Asia and the United States, captive primates,

unlike wild-reared individuals, displayed similar gut microbiome compositions to modern humans, including a predominance of *Prevotella* and *Bacteroides* species. Sanctuary-reared primates that were fed a plant-based diet that included some of the plants available to wild-reared primates displayed middling levels of microbiome diversity and disruption, compared with zoo-reared primates of the same species. Further, microbiome disruption was significantly associated with changes in dietary fiber content, but not with factors such as geographic location and antibiotic use, suggesting that diet largely influences microbiome composition in captive primates. According to the authors, the findings underscore the link between fiber-rich diets and gut microbiome diversity. — P.N.



Red-shanked doucs (*Pygathrix nemaeus*) on Son Tra Peninsula, Vietnam.

Safe, opioid-like pain relief in monkeys

Opioid analgesics such as morphine, which targets mu opioid peptide (MOP) receptors, carry grave risks, including addiction and respiratory arrest due to abuse or overdose. Recent studies have found that nociceptin/orphanin FQ peptide (NOP) receptor agonists, which are used to block the addictive effects of drugs such as morphine, also interact with the MOP agonist buprenorphine to produce an analgesic effect. Huiping Ding et al. (pp. E5511–E5518) present the analgesic analog BU08028, a ligand that exhibits a receptor-binding profile similar to buprenorphine but with greater affinity and efficacy

at NOP receptors. In a series of trials with monkeys, the authors demonstrate that BU08028 targets both MOP and NOP opioid receptors to produce full and lasting pain relief with no corresponding psychological addiction or physical dependence. Furthermore, the study shows that BU08028 does not depress respiratory function or cause cardiac arrest at 10 to 30 times the analgesic dose. Because monkey models faithfully recapitulate human opioid receptor function and drug effects, the findings suggest that mixed MOP/NOP agonists can lead to the development of effective analgesics in humans without risk of abuse and side effects of opioids, according to the authors. — T.J.

